source
- Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.onclive · 2mo ago↗ source
- Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP LossHow Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.onclive · 2mo ago↗ source
- Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast CancerBreast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.